ūüéČ Health Canada Provides a No Objection Letter for ATMA‚Äôs N500 Phase II Clinical Trial Application

VANCOUVER, BC,¬†March 2, 2021¬†/CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”¬†or the¬†“Company”), a leader in developing technology to advance psychedelic-related treatments, is pleased to announce¬†the completion of its initial strategic equity investment of equal to approximately 13% ownership in¬†ATMA Journey Centers Inc.¬†(“ATMA”) in accordance with the terms of the letter of intent (the “LOI”) announced on¬†January 12, 2021.

MINDCURE’s initial strategic investment of¬†$500,000¬†will strengthen our relationship with¬†Calgary-based private healthcare company, ATMA, which has recently provided psychedelic-assisted therapy sessions using psilocybin for patients with section 56 exemptions.1¬†MINDCURE will leverage the growing partnership with ATMA to secure a network of clinics in which to deploy and test MINDCURE’s¬†iSTRYM¬†platform, and concurrently, ¬†provide MINDCURE¬†with access to patient data accelerating the growth of¬†iSTRYM‘s database. This will lead to better diagnoses, treatments and personalized care.

“Our partnership with ATMA represents a huge step forward for healing today in¬†Canada¬†and around the world. By accelerating the development of our research and technology platform, iSTRYM, we’re closer to minimizing the gaps that exist in health care, all the way from research to the deployment of care. It’s an amazing opportunity to innovate with pioneers of the psychedelic therapy industry by creating proprietary research, identifying commonalities, and driving real transformative results for individuals using psychedelic medicines,”¬†said¬†Kelsey Ramsden, President & CEO, MINDCURE.

Access to ATMA’s patient data will contribute to MINDCURE’s proprietary technology,¬†iSTRYM, ultimately helping to optimize treatment for ATMA’s patients and providing a rich data resource for MINDCURE, in accordance with the LOI.

“As the first commercial company in¬†Canada¬†to announce legally treating a palliative patient with psychedelic-assisted therapy using psilocybin, we’re optimistic about the progression to better care options for Canadians. By partnering with MINDCURE, we’re enforcing consistency in terms of protocols, as well as the ability to automate patterns in our patients’ conditions. Overall, this will lead to better patient care, and a stronger foundation for this innovative and leading-edge industry,”¬†said¬†Greg Habstritt, President of ATMA Journey Centers Inc. “Our mission is to deliver effective and innovative healing and transformative experiences that leverage the compelling science around psychedelics. We’re committed to providing the resources, safeguards, expertise, and accessibility into insights that our work uncovers, in order to advocate for better care and new treatment options.”

1¬†“Exemptions,” The Government of Canada (Health Canada, November 13, 2020),¬†https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/exemptions.html

More News and Media:

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

This trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB,¬†Sept. 14, 2022¬†/CNW/ –¬†ATMA Journey Centers Inc.¬†(“ATMA”), an¬†Alberta-based company focused on the international delivery of innovative psychedelic-assisted therapy solutions, announced today that it has received approval from Health Canada to move forward with its N500 Phase II psilocybin

Psychedelic Breakthrough

Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness?

By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner ¬† The Role of Psychedelics in Therapeutic Breakthroughs One of the main goals of psychotherapy is to guide patients toward therapeuticbreakthroughs ‚Äď defined as a significant, sometimes sudden, step forward or important realization. Oftentimes, in therapy, breakthroughs come after long, unproductive plateaus. Such realizations must come from

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  ‚Äď Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, examining the efficacy of psilocybin for Covid-related stress. Calgary, September 7, 2022 ‚ÄĒ‚ÄĮATMA Journey Centers (the ‚ÄúCompany‚ÄĚ), a company providing therapist training and support, has

Thank You Letter

Dear mental healthcare professionals, A deep heart-felt thank you is warranted to you for bearing the weight of the current mental health crisis, especially during these last tough couple of years. I have heard from many of your peers regarding the increased pressure, overburdening workloads, and feelings of burnout that have become an all too frequent occurrence.

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Scroll to Top